Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 3/20 | 0.51 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.51 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.47 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.47 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.47 |
| ▸ | HTR3E | A5X5Y0 | 3/20 | 0.45 |
| ▸ | HTR3B | O95264 | 3/20 | 0.45 |
| ▸ | HTR3A | P46098 | 3/20 | 0.45 |
| ▸ | HTR3D | Q70Z44 | 3/20 | 0.45 |
| ▸ | HTR3C | Q8WXA8 | 3/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.42 |
| ▸ | HRH1 | P35367 | 2/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.42 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4088881 | 1.00 | SLC6A2 (0.51) | SLC6A2SLC6A3CHRM4CHRM5CHRM2 | |
| SCHEMBL1177914 | 0.94 | SLC6A2 (0.58) | SLC6A2SLC6A3CHRM4CHRM5CHRM2 | |
| SCHEMBL1177917 | 0.94 | SLC6A2 (0.58) | SLC6A2SLC6A3CHRM4CHRM5CHRM2 | |
| SCHEMBL3981050 | 0.87 | SLC6A2 (0.47) | SLC6A2SLC6A3CHRM4CHRM5CHRM2 | |
| SCHEMBL3981052 | 0.87 | SLC6A2 (0.47) | SLC6A2SLC6A3CHRM4CHRM5CHRM2 | |
| Fumaric Acid SCHEMBL1177442 | 0.84 | HTR3E (0.50) | SLC6A2SLC6A3CHRM4CHRM5CHRM2 | |
| SCHEMBL1177519 | 0.81 | SLC6A2 (0.53) | SLC6A2SLC6A3CHRM4CHRM5CHRM2 | |
| SCHEMBL1177518 | 0.81 | SLC6A2 (0.53) | SLC6A2SLC6A3CHRM4CHRM5CHRM2 | |
| SCHEMBL7332694 | 0.79 | SLC6A2 (0.54) | SLC6A2SLC6A3CHRM4CHRM5CHRM2 | |
| SCHEMBL1178226 | 0.79 | SLC6A2 (0.54) | SLC6A2SLC6A3CHRM4CHRM5CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7524958-B2 | Certain 9-aza-bicyclo[3.3.1] nonane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors | NEUROSEARCH A/S (DK) | 2009-04-28 | — | — | US | claimed |
| US-20070232641-A1 | Novel 9-Aza-Bicyclo[3.3.1]Nonane Derivatives and Their Use as Monoamine Neurotransmitter Re-Uptake Inhibitors | NEUROSEARCH A/S (DK) | 2007-10-04 | — | — | US | claimed |
| EP-1761527-A1 | NOVEL 9-AZA-BICYCLO¬3.3.1|NONANE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2007-03-14 | — | — | EP | claimed |
| WO-2005123728-A1 | NOVEL 9-AZA-BICYCLO[3.3.1]NONANE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2005-12-29 | — | — | WO | claimed |
| US-7524958-B2 | Certain 9-aza-bicyclo[3.3.1] nonane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors | NEUROSEARCH A/S (DK) | 2009-04-28 | — | — | US | disclosed |
| US-20070232641-A1 | Novel 9-Aza-Bicyclo[3.3.1]Nonane Derivatives and Their Use as Monoamine Neurotransmitter Re-Uptake Inhibitors | NEUROSEARCH A/S (DK) | 2007-10-04 | — | — | US | disclosed |
| EP-1761527-A1 | NOVEL 9-AZA-BICYCLO¬3.3.1|NONANE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2007-03-14 | — | — | EP | disclosed |
| WO-2005123728-A1 | NOVEL 9-AZA-BICYCLO[3.3.1]NONANE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2005-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232641-A1 | Novel 9-Aza-Bicyclo[3.3.1]Nonane Derivatives and Their Use as Monoamine Neurotransmitter Re-Uptake Inhibitors | SLC18A2, SLC6A2, SLC18A3 | SLC6A2 2/4885SLC6A3 4/4885CHRM4 291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.